CME Nuclear medicine

Edited by Val Lewington, professor of clinical therapeutic nuclear medicine, King's College London and honorary consultant in nuclear medicine, Guy's and St Thomas' NHS Foundation Trust

Nuclear medicine functional imaging of the brain

Simon J Hughes *consultant in radiology and nuclear medicine, Royal Victoria Hospital, Belfast*

If the 20th century was the century of the development of structural imaging of disease, the 21st has the potential to be that of functional imaging. Significant advances in technology now allow structural and functional data to be combined to define and subclassify clinical disease, and thus guide management.

Structural imaging is widely used to assess both tumour development and brain atrophy. Abnormalities are often seen in the final stages of disease when the clinical importance of these changes in terms of influencing outcome may be low. Functional changes occur much earlier in disease processes and, if detected, may have a greater impact on clinical care.

Most types of functional nuclear medicine brain imaging involve the use of picomolar amounts of radiopharmaceutical to image changes in receptor expression and other uptake mechanisms in the normal brain. Pathological overexpression of receptor density or loss of normality in uptake pathways reflects changes in the blood-brain barrier (BBB), glial cells and neurones. Imaging these changes at an early stage has the potential for improved diagnosis and can inform management decision making.

This review concentrates on common clinical problems for which nuclear medicine is clinically useful in routine practice.

The field is advancing rapidly and future applications of new tracers will also be discussed briefly.

Dementias

Dementias are a group of diseases given a complex definition in the International Classification of Disease, 10th Edition (ICD 10), highlighting the challenges faced by clinicians who investigate and manage neurodegenerative disease:

> ... syndromes due to disease of the brain, usually of a chronic and progressive nature, in which there is impairment of higher cortical functions, including memory, thinking, orientation, comprehension, calculation, learning capacity, language and judgment. The cognitive impairments are commonly accompanied and occasionally preceded by deterioration in emotional control, social behaviour or motivation.

Functional nuclear medicine techniques are increasingly used to diagnose dementia, the incidence of which is increasing. In the UK, over 800,000 people live with the diagnosis, imposing an economic burden of over £23 billion over and above the human cost.[1]

The 'despair diagnosis' often associated with dementia should be addressed - to the extent that the value of early diagnosis has been questioned in the absence of curative treatment. By contrast, the 2005 Department of Health strategy document, *Living well with dementia*[2] stated:

> Research shows that early intervention in cases of dementia is cost effective and can improve the quality of life for people with dementia and their families.

Preliminary data presented at the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in 2010 (Dementia Demonstration Project) show that prompt diagnosis of dementia saves money, even early in the course of disease.[3] Most agencies now advocate early diagnosis as an important factor in the successful management of dementia.

Clinical presentation

Clinical presentation is highly variable and complex. First results from the Rush Memory and Aging Project[4] show that '… correlation of the clinical definition of disease and pathology is poor'. There is therefore a compelling role for biomarkers to guide diagnosis and management.

Diagnosis

(^{18}F)-Fluoro-deoxyglucose PET/CT

The most important radiopharmaceutical in the diagnosis of dementia is (^{18}F)2'-fluoro-2'-deoxy-D-glucose (FDG). Its distribution is assessed using a combined PET/CT scanner (Fig 1). This technique images altered expression of glucose transporters (GLUT) in the BBB, glial cells and neurones. FDG has a major role in characterising 'intrinsic neurodegenerative dementias' such as:

- Alzheimer's disease (AD)
- dementia with Lewy Body (DLB) (previously Pick disease, but now a broader and more accurate disease spectrum of alpha-synucleinopathies) (Fig 2)
- frontotemporal dementia (FTD) and its variants.

Alzheimer's disease. In AD, the most common form of dementia, complex changes include decrease in GLUT 1 and 3 on the BBB and neurones, respectively, and increased GLUT 3 on glial cells.[5] These changes partly reflect the loss of excitatory glutamate synapses secondary to the neurotoxic processes associated with dementia. In AD, these neurotoxic effects derive from soluble amyloid protein from the cleavage of the amyloid precursor protein (APP).[6]

Other dementias. FDG also has the potential to identify early abnormalities in other forms of dementia. The Rush Memory and Aging Project[4] demonstrated that most patients have mixed pathology which is

Fig 1. Axial images of FDG PET distribution in the brain at the level of the body of the lateral ventricles. Both patients presented with possible early dementia and MMSE scores of 28/30. (a) Normal comparative distribution of activity in the frontal and parietal lobes, with no significant loss of activity. (b) Clear evidence of disease with severe loss of activity in both temporoparietal lobes and moderate activity in the frontal lobes. Between these regions, there is relative maintenance of activity in the sensorimotor cortex on both sides – a good clinical indicator of the presence of an intrinsic neurodegenerative dementia on the scan. Activity is also maintained in the occipital lobes. There is also loss of comparative activity in the posterior cingulate gyri (white arrow), a relatively specific regional sign for the presence of Alzheimer's disease.

likely to be increasingly recognised by the medical profession. FDG is of less value in defining vascular dementia[7] and no role in the investigation of dementia arising as the result of genetically determined biochemical abnormalities, trauma, inflammatory, infective, toxic or metabolic causes. In clinical practice, FDG is rarely indicated for dementias associated with Huntington's disease, progressive supranuclear palsy, Parkinson's disease (PD)-related dementia, idiopathic thalamic degeneration or Fahr's disease.

FDG in clinical practice. A recent trial by Caroli *et al*[8] compared automated assessments of FDG distribution in subjects with AD, mild cognitive impairment (MCI) and normal controls. The accuracy of the assessments, measured as area under the curve, in 650 subjects ranged from 0.774-0.983. This large number of assessments in an ongoing study suggests an important role for FDG in clinical practice.

A review of the literature by Bohnen *et al*[9] shows that:

… the evidence for (18)F-FDG PET in assessment of dementia has increased with new studies that include autopsy confirmation, wide-diagnostic-spectrum recruitment in primary care settings, historical and prospective cohort studies, and multicenter data analyses.

Mosconi *et al*[10] adopted a standardised automated analysis of FDG PET brain studies of 548 patients. The study population was considered representative of the clinical situation in the memory clinic (110 normal, 114 MCI, 199 AD, 98 FTD, 27 DLB subjects). It was found that 95% of AD, 92% of DLB, 94% of FTD and 94% of normals were correctly classified.

In a retrospective study, Laforce *et al*[11] demonstrated that FDG imaging led to a change in diagnosis in 29% of patients with suspected dementia, a reduction in unclear diagnosis from 39–16%, the clinical impact being greatest in unclear and atypical cases.

Plaque burden

Imaging of 'plaque burden' in AD is important because AD is partly defined by the presence of beta-amyloid plaques in the extracellular space and neurofibrillary tangles in the neurones. Their presence has recently been reconfirmed as a defining characteristic of the disease in a large


Fig 2. Image of the semi-automated assessment of FDG activity in the brain in which the observed activity is subtracted from a bank of age-matched controls, showing lateral (a) and medial (b) images of the right hemisphere. There is loss of activity in the temporoparietal right lateral lobe, with further loss in the occipital lobe. Changes in the occipital lobe are the most accurate discriminator of the presence of dementia with Lewy body (DLB). (c) With the development of multislice PET/CT scanners, coronal reconstructions of the brain allow assessment of the medial temporal lobe volumes, graded normal in this patient, adding further evidence to the diagnosis of DLB rather than Alzheimer's disease.

review of cases with pathological confirmation.[12] The study also confirmed that, although beta-amyloid plaques may play a key role in AD pathogenesis, the severity of cognitive impairment correlates best with the burden of neocortical neurofibrillary tangles.

In 25–45% of autopsy brain examinations from cognitively normal elderly people the

Fig 3. Two axial PET/CT images in a patient with a past history of high-grade oligodendroglioma of the right frontal lobe previously treated with chemoradiotherapy. An MRI had shown equivocal findings, with clinical suspicion of recurrent disease.
(a) Low attenuation radionecrosis is seen with no abnormal FDG uptake in this area.
(b) Abnormal FDG uptake is seen in the inferoposterior aspect of the previous treatment field (arrow), confirmed as recurrent disease on PET-guided biopsy.

Key points

The role of functional imaging with nuclear medicine techniques in neurology is well established and continues to expand rapidly

[18]Fluorodeoxyglucose (FDG) is a defining biomarker in clinical dementia

Magnetic resonance imaging (MRI) assessment of regional atrophy and cerebrospinal fluid oligomer amyloid measurement are also potential biomarkers for Alzheimer's disease, but the clinical breadth of FDG in many types of dementia increases its clinical usefulness

[123]I-Ioflupane is well established for the diagnosis of early idiopathic Parkinson's disease and is of value in assessing dementia with Lewy body

In the difficult differentiation of recurrent primary brain tumour from benign radionecrosis, functional nuclear medicine imaging improves decision making and clinical management

KEYWORDS: nuclear medicine, dementia, Parkinsonian syndromes, primary brain tumours, plaque imaging, FDG, FP-CIT, ioflupane, MIBI

plaque deposition is indistinguishable from AD, indicating that neuronal loss, synaptic loss and atrophy are all required for the development of neuropsychopathology.[13,14]

There is considerable research interest in the development of plaque imaging agents such as ^{11}C-Pittsburgh compound B (^{11}C-PIB), 18F-flutametamol and 18F-florbetabir. These agents are being used to define the presence of beta-amyloidosis of the brain (BAB). BAB is seen in AD and is a risk factor for its development, but is also observed in cognitively normal individuals. At present, understanding of the cascade of APP cleavage by various secretases, production of possible neurotoxic dimers, development of oligomers, fibrils, beta-pleated sheets and beta-amyloid plaques is limited.

It is likely that plaque imaging will play a role in the selection of 'at risk' patients for treatment, the leading target for therapy being beta-amyloid dimers.[15] Other options may include gamma-secretase inhibitors, secretase modulators, prevention of oligomer formation, increased removal of plaque and intravenous immunoglobulin.[16-18] It is not clear whether plaque burden would be expected to increase or decrease as a result of successful treatment.

Parkinsonian syndrome

The group of diseases known as the Parkinsonian syndrome includes idiopathic PD (IPD) and the Parkinsonian-plus syndromes (multisystem atrophy, progressive supranuclear palsy and corticobasilar degeneration). The pathology of IPD is defined by the presence of Lewy bodies which fall within the same spectrum of pathology observed in DLB.[19] Loss of neuronal cells occurs in the substantia nigra in the brain stem (pathological stage 3-4). The substantia nigra neurones send vulnerable unmyelinated long axons into the basal ganglia to produce dopaminergic synapses where movement control is modulated by their action. Parkinsonian symptoms develop when approximately 60–70% of neuronal cells and their axons are lost.

Ioflupane ([^{123}I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane, or FP-CIT) is a radiopharmaceutical

which targets presynaptic dopamine reuptake transporters in the brain, the highest density being found in the basal ganglia. A qualitative reduction in selective tracer uptake occurs in the presence of Parkinsonian syndromes and reflects the typical onset of clinical symptoms in stage 3–4 disease. In a recent review of the major multicentre ioflupane studies, an abnormal scan predicted the development of IPD at three years with an accuracy of 78–97%.[20] The negative predictive value of a normal scan was 92–97%.

Ioflupane is now established as a useful study in the differentiation of essential tremor from IPD, a normal result indicating a low probability of IPD. There has been interest in using ioflupane in the differentiation of IPD from the Parkinsonian-plus syndromes, but this has proved challenging and is not considered routine clinical practice at present.[21,22] It is also of value in assessing DLB.[23]

Primary brain tumours

A detailed summary of all the tracers developed for neuro-oncology lies beyond the scope of this review. The most clinically useful indication for nuclear medicine imaging at present is the investigation of suspected recurrence in high-grade primary brain tumours using FDG PET/CT.

The treatment of high-grade tumours involves chemoradiotherapy which induces radionecrosis in the region treated. The distinction of radionecrosis from recurrent tumour using magnetic resonance imaging (MRI) is challenging and unreliable. Higher accuracy has been shown using FDG PET/CT. In a retrospective study of 117 consecutive patients with non-diagnostic post-treatment MRI and CT examinations, the positive (PPV) and negative (NPV) predictive values of [18]FDG PET for tumour recurrence were 96% and 55.6%, respectively. A negative scan was associated with significantly prolonged overall survival.[24]

MIBI

In an interesting study of 81 patients, ^{99m}Tc-methoxy-isobutylene-isonitrile (MIBI) was used to discriminate between radionecrosis and recurrent disease.[25] This tracer is used routinely in all nuclear medicine departments, is easily available and imaged using a conventional gamma camera with tomographic capability (SPECT). The overall sensitivity, specificity and accuracy of the technique was 90%, 91.5% and 90.5%, respectively, with 91%, 100% and 95%, respectively, for detection of more difficult, low-grade tumour recurrence. In addition, MIBI proved useful in detecting anaplastic transformation of low-grade recurrent tumours.

Other PET tracers

Other PET tracers used to assess primary tumours include amino acid analogues which allow imaging of both high- and low-grade tumours. ^{18}F-fluoro-ethyl-tyrosine was used in a study of 53 patients, of whom 43 had high-grade and 10 low-grade tumours.[26] All recurrences were detected, with no false negative results and an accuracy of 100%.

[18]F-fluoro-dihydroxyphenylalanine (DOPA) also shows promise in the assessment of malignant glioma, particularly in patients with suspected recurrence. A prospective study of eight patients demonstrated an overall sensitivity and specificity of 98% and 86%, respectively, with PPV 95% and NPV 95%. The sensitivity of ^{18}F-DOPA in low-grade tumours was superior to that of FDG.[27]

References

1 Luengo-Fernandez R, Leal J, Gray A. *Dementia 2010. The economic burden of dementia and associated research funding in the United Kingdom.* Cambridge: Alzheimer's Research Trust, 2010.

2 Department of Health. *Living well with dementia: a national dementia survey.* London: DH, 2005.

3 McCarten JR, Anderson O, Kuskowski MA *et al.* Alzheimer's Association International Conference on Alzheimer's Disease (ICAD). Abstract O4-04-04. 10-15 July 2010.

4 Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. *Ann Neurol* 2009;66:200–8.

5 Liu Y, Liu F, Grundke-Iqbal I *et al.* Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. *J Neurochem* 2009;111:242–9.

6 McDonald JM, Savvy GM, Brayne C *et al*; Medical Research Council Cognitive Function and Ageing Study. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. *Brain* 2010;133:1328–41.

7 Sahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular risk factors; a review. *Int J Stroke* 2012;7:61–73.

8 Caroli A, Prestia A, Chen K *et al.* EADC-PET Consortium, NEST-DD, and Alzheimer's Disease Neuroimaging Initiative. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. *J Nucl Med* 2012;53:592–600.

9 Bohnen NI, Djang DS, Herholz KP *et al.* Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. *J Nucl Med* 2012;53:59–71.

10 Mosconi L, Tsui WH, Herholz K *et al.* Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. *J Nucl Med* 2008;49:390–8.

11 Laforce R Jr, Buteau JP, Paquet N *et al.* The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: A retrospective memory clinic study. *Am J Alzheimers Dis Other Demen* 2010;25:324–32.

12 Nelson PT, Alafuzoff I, Bigio EH *et al.* Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *J Neuropathol Exp Neurol* 2012;71:362–81.

13 Bennett DA, Schneider JA, Arvanitakis Z *et al.* Neuropathology of older persons without cognitive impairment from two community-based studies. *Neurology* 2006;66:1837–44.

14 Price JL, Morris JC. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. *Ann Neurol* 1999;45:358–68.

15 Mucke L, Selkoe DL. Neurotoxicity of Amyloid â–protein: Synaptic and Network Dysfunction. *Cold Spring Harb Perspect Med* 2011. doi: 10.1101/cshperspect.a006338.

16 Imbimbo BP, Giardina GA. ã-Secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. *Curr Top Med Chem* 2011;11:1555–70.

17 Grill JD, Cummings JL. Current therapeutic targets in the treatment of Alzheimer's disease. *Expert Rev Neurother* 2010;10:711–28.

18 Dodel R, Neff F, Noelker C *et al*. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. *Drugs* 2010;70:513–28.

19 Braak H, Ghebremedhin E, Rüb U *et al*. Stages in the development of Parkinson's disease-related pathology. *Cell Tissue Res* 2004;318:121–34.

20 Hauser RA, Grosset DG. [(123) I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. *J Neuroimaging* 2011 Mar 16. (ahead of print)

21 Antonini A, Benti R, De Notaris R *et al*. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. *Neurol Sci* 2003;24:149–50.

22 Filippi L, Manni C, Pierantozzi M *et al*. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study. *Nucl Med Commun* 2006;27:381–6.

23 Antonini A. The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. *Neuropsychiatr Dis Treat* 2007;3:287–92.

24 Wang SX, Boethius J, Ericson K. FDG-PET on irradiated brain tumor: ten years' summary. *Acta Radiol* 2006;47:85–90.

25 Le Jeune FP, Dubois F, Blond S, Steinling M. Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies. *J Neurooncol* 2006;77:177–83.

26 Pöpperl G, Kreth FW, Mehrkens JH *et al*. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. *Eur J Nucl Med Mol Imaging* 2007;34:1933–42.

27 Chen W, Silverman DH, Delaloye S *et al*. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. *J Nucl Med.* 2006;47:904–11.

Dr S J Hughes, Royal Victoria Hospital, Belfast HSC Trust, Grosvenor Road, Belfast BT12 6TB.
Email: dr.simon.hughes@gmail.com